Candel Therapeutics Poised for Breakthrough in Cancer Therapies, Key Trials to Read Out by Year-End | NASDAQ:CADL
Daily options tracking | Nvidia's stock price hit a three-month high, with the highest increase in call options nearly tripling; China concept ETF cools down, with a significant decrease in volatility.
tesla rose slightly by 1.52%, the call options with expiration dates of this Friday at 245 and 250 US dollars were the most active, Robotaxi conference tickets have been issued, the event is scheduled for 10 am this Friday morning peking time.
This Insider Has Just Sold Shares In Candel Therapeutics
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics, Inc. (NASDAQ:CADL) Most Popular Amongst Individual Investors Who Own 48%, Insiders Hold 30%
Express News | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Candel Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Candel Therapeutics - on Track for Topline Disease-Free Survival Data From Phase 3 Randomized Controlled Clinical Trial of Can-2409
Express News | Candel Therapeutics Inc- Sees Existing Cash & Cash Equivalents Will Be Sufficient to Fund Current Operating Plan Into Q1 2025
Earnings Flash (CADL) CANDEL THERAPEUTICS Posts Q2 Loss $-0.74 Per Share
Candel Therapeutics 2Q Research and Development Expenses $5.0M >CADL
Express News | Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Express News | Candel Therapeutics Q2 Net Income USD -22.237 Million
Express News | Candel Therapeutics Q2 Income From Operations USD -8.571 Million
Express News | Candel Therapeutics Q2 Basic EPS USD -0.74
Express News | Candel Therapeutics Q2 Operating Expenses USD 8.571 Million
Press Release: Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing